Comprehensive medication guide to Ajovy including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$50/month
Estimated Cash Pricing
$690–$1,019/month
Medfinder Findability Score
68/100
Summarize with AI
On this page
Ajovy (Fremanezumab-Vfrm) is a prescription injectable medication used for the preventive treatment of migraine in adults and pediatric patients aged 12 years and older (weighing at least 45 kg). It belongs to a class of drugs called CGRP inhibitors (calcitonin gene-related peptide inhibitors). Ajovy is manufactured by Teva Pharmaceuticals and was designed specifically to reduce the number of migraine days per month — it is not used to treat a migraine attack that has already started.
Ajovy is self-administered as a subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. Patients can choose between monthly or quarterly dosing, making it one of the more flexible options among injectable CGRP preventive treatments.
225 mg/1.5 mL prefilled syringe
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
for monthly or quarterly dosing
225 mg/1.5 mL prefilled autoinjector (pen)
for monthly or quarterly dosing
Ajovy has a relatively favorable side effect profile compared to older migraine preventives. The most commonly reported issues are local injection site reactions, which are typically mild and resolve on their own. Serious side effects are rare but can include hypersensitivity reactions such as rash, hives, and in very rare cases, anaphylaxis or angioedema (swelling of face, tongue, or throat). Seek immediate medical attention if you experience signs of a severe allergic reaction.
Know what you need? Skip the search.
Aimovig (Erenumab)
an injectable CGRP receptor blocker for migraine prevention, given monthly via autoinjector
Emgality (Galcanezumab)
an injectable CGRP inhibitor for migraine and cluster headache prevention, given monthly
Vyepti (Eptinezumab)
an IV-infused CGRP inhibitor for migraine prevention, given quarterly in a healthcare setting
Qulipta (Atogepant)
an oral CGRP receptor antagonist for migraine prevention, taken daily as a tablet (no injections needed)
Prefer Ajovy? We can find it.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards